Moderna stock soars 177%, Merck jumps 12% after cancer vaccine shows promise in late-stage trial
The personalized vaccine cut the risk of melanoma returning or spreading in Phase 3 trials, and the companies plan to seek regulatory review.
- On Wednesday, Merck and Moderna announced that a personalized mRNA-based cancer vaccine succeeded in a Phase 3 trial, significantly reducing recurrence risk in high-risk melanoma patients when paired with Merck's Keytruda immunotherapy.
- Previous Phase 2b trial results established the efficacy baseline, showing the treatment reduced melanoma recurrence by 49% and metastasis to distant organs by 59% in patients after surgical tumor removal.
- H. Lee Moffitt Cancer Center & Research Institute oncologist Dr. Ahmad Tarhini called the approach "individualized neoantigen therapy," explaining that genetic sequencing creates a "unique mutational fingerprint" to help the immune system attack cancer.
- Moderna president Stephen Hoge said the vaccine could be available by next year if regulators approve the treatment, though the FDA must first review full data the companies plan to present soon.
- Expanding beyond melanoma, where the American Cancer Society expects 112,000 new cases in 2026, mRNA technology is currently in trials for bladder, kidney, lung, stomach, and pancreatic cancers.
146 Articles
146 Articles
Centers in Barcelona, Madrid, Malaga and Valencia were the setting for this medical milestone
mRNA technology may be about to make one of its biggest jumps since the vaccines against COVID-19. This time, the target is cancer and the first phase 3 results...
Merck and Moderna report success in the development of an mRNA vaccine against black skin cancer. Combination therapy is intended to prevent relapses and the spread of the disease.
The two American laboratories announced on Wednesday August 19th positive results in the final phase of clinical trials of their experimental vaccine against advanced melanoma, a first to...
Moderna and Merck say melanoma vaccine succeeded in large trial - Boston News, Weather, Sports
(CNN) — A personalized mRNA cancer vaccine combined with the immunotherapy Keytruda succeeded in a late-stage trial for the deadly skin cancer melanoma, its makers said...
Coverage Details
Bias Distribution
- 44% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
